Related Articles
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas
O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer
Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas
LOHÂ 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation